About
Phil Patten joined DiCE Molecules as chief scientific officer in May 2014. Prior to DiCE Molecules, Phil Patten served at Pioneer HiBred, where he was a DuPont Fellow, research director and led a team of 90 scientists doing directed evolution of proteins and large-scale synthetic biology in the agricultural space. Prior to Pioneer HiBred, Phil Patten served as senior vice president of biology at Achaogen, where he led the DTRA-funded LpxC program to the discovery of ACHN-975, a small molecule now in Phase 1b with several backup clinical compounds. In addition, he also served as vice president of technology at Maxygen, a pioneer in the field of directed protein evolution via gene shuffling. While at Maxygen, he led the team that produced an improved gene shuffled interferon alpha that entered clinical trials. He is also a named inventor on an evolved herbicide tolerance gene (GAT) that is in late-stage commercial development. Phil Patten has been actively involved in the practice of
Investment Focus
- Location
- San Francisco, US
Contact Information
Find more investors like Phil
Search Investors